Time to blur the blast boundaries
Courtney D. DiNardo, Guillermo Garcia‐Manero, Hagop M. Kantarjian
Abstract
A fixed 20% blast percentage to discriminate myelodysplastic neoplasms from acute myeloid leukemia is arbitrary and overly simplistic. Key factors for identifying the optimal therapy for a patient with a myeloid malignancy should rely most on the patient's characteristics (particularly age and fitness/frailty) and disease cytogenetic and mutational profile, with less reliance on the bone marrow blast percentage.
Topics & Concepts
MedicineMyeloid leukemiaMyelodysplastic syndromesMalignancyDiseaseMyeloidBone marrowBone marrow failureLeukemiaOncologyInternal medicineHaematopoiesisGeneticsStem cellBiologyAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentHematological disorders and diagnostics